Knockout Mouse Catalog | Cyagen APAC

Glaucoma is a group of eye diseases that damage the optic nerve, many types of which have no warning signs. The effects of the disease appear gradually as fluid builds up in the eye, so the patient may not notice changes in vision until the disease is advanced. The health of the optic nerve is critical to maintaining good vision. Because vision loss caused by glaucoma is irreversible, it is important to have regular eye exams, including measuring intraocular pressure (IOP), so patients can be diagnosed early and begin treatment.

As the second leading cause of blindness globally, glaucoma can occur without an exact cause due to the numerous factors affecting its pathology. There are several animal models used to research the various pathological factors of glaucomas and also demonstrated the potential efficacy of targeted glaucoma gene therapy. How much do you really know about glaucoma?


What is Glaucoma?

Glaucoma is a group of diseases characterized by atrophy and depression of the optic disc, visual field defect, and decreased visual acuity. The pathological IOP and optic nerve ischemia are the risk factors for primary glaucoma. In addition, the tolerance of the optic nerve to pressure and damage is also related to the occurrence and development of glaucoma. Any blockage in any part of the aqueous humor circulation of the human eye can lead to increased IOP and glaucoma.

Glaucoma is the second leading cause of blindness in the world, with an incidence of 1% of the general population and 2% of people over the age of 45. Clinically, glaucoma is divided into three categories — primary, secondary, and congenital — according to the etiology, anterior chamber angle, IOP, and other conditions.


Figure 1. Overview of Open-Angle Glaucoma and Neovascular Glaucoma

(Source: Rare Disease Data Center)


The underlying cause of primary angle closure glaucoma is mainly pupillary block, while in secondary forms there are other underlying causes that either push or pull the iris to contact trabecular meshwork, a critical determinant of IOP values. Secondary glaucoma is caused by certain ocular or systemic diseases that interfere with normal aqueous humor circulation, such as traumatic glaucoma, neovascular glaucoma,  iridocyclitis-associated secondary glaucoma, and glucocorticoid-induced glaucoma. The causes of the above-mentioned ocular diseases are relatively clear. Congenital glaucoma is caused by abnormal embryonic development and congenital anterior chamber angle structural variation. Primary congenital glaucoma (PCG) is a rare disease caused by genetically-determined abnormalities in the anterior chamber angle and trabecular meshwork resulting in elevated IOP.


Figure 2. Clinical Manifestations of Acute Angle-Closure Glaucoma

(Source: Health Plus; Du Toit N et al, 2013)


Association of Disease Symptoms with Pathogenesis

Neovascular glaucoma (NVG) refers to glaucoma caused by the formation of new fibrovascular membranes on the surface of the iris and trabeculae, leading to the adhesion of the peripheral anterior iris and hindering the drainage of aqueous humor. It is refractory glaucoma secondary to extensive retinal ischemia (eg, retinal vein occlusion, diabetic retinopathy). NVG is irreversible, with a high risk of blindness and long-term eye and head pain [1].

Primary open-angle glaucoma (POAG) is an irreversible blinding disease mainly manifested by optic nerve damage and visual field defects. The essence is retinal ganglion cell (RGC) damage. The mechanistic theory believes that the cause of the disease is that the IOP rises beyond the tolerable limit of the optic nerve, which changes the structure of the optic nerve lamina cribrosa, thereby causing mechanical damage to the nerve fibers. Further research has shown that because the optic nerve axoplasmic transport was blocked in the optic nerve lamina cribrosa, the axonal membrane was unable to use mitochondria to generate ATPase, and the axonal protein synthesis and transport were reduced due to metabolic problems, resulting in impaired cell function and spontaneous apoptosis. The vascular theory believes that ischemia caused by vasospasm is the main reason for the pathogenesis of POAG [3].

Primary angle-closure glaucoma (PACG), characterized by anterior chamber angle closure, elevated IOP, and glaucomatous optic neuropathy, is the most common type of glaucoma in China and the leading cause of irreversible blindness in Asia. Different from primary open-angle glaucoma (POAG), the narrow anterior segment and anterior chamber angle structure are the basic anatomical features of PACG, and the process of gradually narrowing and closing the anterior chamber angle is quite complicated and involves many factors [2].


Animal Models of Glaucoma

Spontaneous Animal Models

Spontaneous animal models of  glaucoma include spontaneously (inherited) or artificially genetically modified (transgenic) lines which develop the disease characteristics without external induction; they are of great value for preclinical in vivo studies of glaucoma. Herein, we discuss three such spontaneous mouse models of glaucoma, their clinical phenotype, and research applications.


Mouse Model

Clinical Phenotype


Optic nerve axon atrophy


Spontaneous Retinal Ganglion Cell (RGC) death and optic neurodegeneration without concomitant IOP elevation


Table 1. Representative Genetically Modified Mouse Models of Spontaneous Glaucoma


● DBA/2J/Pax6-Norrin

The DBA/2J mouse is one of the most informative mouse models since it shares many similarities with human glaucoma. As an age-dependent model of hereditary ocular hypertension, it is widely used in glaucoma research. This model has typical features of glaucoma injury, with spontaneous anterior segment abnormalities (anterior chamber deepening, corneal edema, etc.), iris atrophy, peripheral iris adhesions, and pigment dispersion, resulting in elevated IOP from about 8 months of age. It should be noted, however, that the extent of RGC damage varies greatly between individuals.

A study has reported that DBA/2J/Pax6-Norrin mice, obtained by crossing transgenic mice (Pax6-Norrin) that overexpress Norrin in the retina with DBA/2J mice, have a significantly higher survival rate of optic nerve axons in the 1-year-old group than that in the littermate DBA/2J group. The study provides a possible new target for glaucoma treatment involving Norrin. The main advantage of transgenic animal models of glaucoma is the small inter-individual variability in responses to elevated IOP, retinal and optic nerve damage. More importantly, the application of transgenic animal models helps to identify interactions between disease-causing loci.[4]


In addition to spontaneous ocular hypertension glaucoma models, spontaneous normal tension glaucoma (NTG) mouse models have also been reported. Deletion of the glutamate/aspartate transporter (GLAST) and excitatory amino acid carrier 1 (EAAC1) resulted in spontaneous RGC death and optic neurodegeneration without concomitant IOP elevation. Its pathological process is similar to that of NTG.

Harada et al. [6] summarized the advantages and limitations of various established glaucoma animal models, including GLAST knockout mice, EAAC1 knockout mice, optic nerve protein E50K knock-in mice, DBA/2J mice, and experimental induction models. Among them, GLAST knockout mice, EAAC1 knockout mice, and optic nerve protein E50K knockin mice developed RGC degeneration, but no abnormal IOP. Retinal degeneration in these mice occurred at 3-5 weeks of age, with earlier onset and faster progression than expected in human glaucoma. Findings from animal models of ocular hypertension are also helpful in studying NTG. Considering the therapeutic potential of these models together may facilitate the development of new therapies targeting non-IOP factors, such as RGC degeneration.


Figure 3. Related Mouse Models of Open-Angle Glaucoma

(Source: Rare Disease Data Center)


Induced Animal Models

In addition to spontaneous genetically modified animal models, induced animal models are also used in the study of glaucoma. The specific induction methods can be roughly divided into six types according to the methodology: injection of specific substances into the anterior chamber; steroid induction; laser photocoagulation of the aqueous humor outflow channel; laser, cautery, or ligation of the episcleral vein; circumlimbal suture[4].


Gene Therapy: New Strategies for Treatment

In recent years, the underlying genetic factors of numerous eye diseases have been identified and the development of related animal models has contributed to major breakthroughs in preclinical research. Gene therapy is increasingly being used in the targeted therapy of eye diseases, including glaucoma.

Case Study: Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9

  1. Experimental idea: Knockout the Aqp1 gene in the ciliary body to reduce IOP
  2. Selection and validation of serotypes of AAV targeting ciliary epithelium 
  3. Virus packaging 
  4. Verification of knockout ability in vitro
  5. Virus injection and in vivo efficacy validation (IOP measurement, RGC count, structural scan, frozen slice, etc.)

The authors reduced IOP by disrupting aquaporin 1 (Aqp1) in the ciliary body using AAV-delivered CRISPR-Cas9. Aquaporins are a family of water-transporting transmembrane proteins that are widely expressed in humans. Transgenic mice lacking Aqp1 have been shown to have lower IOP due to reduced aqueous humor formation and inflow.[5]


Figure 4. Adeno-Associated Virus ShH10 Serotype Efficiently Transduces Ciliary Body Epithelium following Intravitreal Injection


Figure 5. Aquaporin 1 Is Expressed in the Mouse Ciliary Body and Can Be Targeted Using CRISPR-SaCas9


Figure 6. CRISPR-Cas9-Mediated Disruption of Ciliary Body Aquaporin 1 Lowers Intraocular Pressure in the Mouse


Figure 7. Ciliary Body Aquaporin 1 Disruption Lowers Intraocular Pressure in Two Experimental Glaucoma Models and Prevents Ganglion Cell Loss




[1] Wanqiu Ma.Advances in the treatment of neovascular glaucoma[J]. Chinese Journal of Urban and Rural Industrial Hygiene,2022,37(03):30-32.DOI:10.16286/j.1003-5052.2022.03.011.

[2] Yongqi Chai, Linan Guan, Weiwei Gao. Advances in imaging studies of anterior chamber angle in primary angle-closure glaucoma[J]. Medical Review,2021,27(16):3268-3273.

[3] Jing Tang, Yingping Deng, Qiong Wang, Xiaoming Chen. Research progress on the pathogenesis of primary open-angle glaucoma[J]. NRecent Advances in Ophthalmology,2020,40(06):587-592.DOI:10.13389/j.cnki.rao.2020.0135.

[4] Shuo Song, Yong Meng, Hua Li. Application of glaucoma animal model in glaucoma research [J]. Journal of Nanjing Medical University (Natural Science Edition),2021,41(12):1850-1855.

[5] Wu J, Bell OH, Copland DA, et al. Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9. Mol Ther.2020;28(3):820-829.

[6] Harada T, et al. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest. 2007 Jul;117(7):1763-70.


  • Contact Us

    We will respond to you in 1-2 business days.


    The username is required


    The user's email is required

    Please enter a valid email address.


    The content is required